focus -WSS

focus

author：Wikipedia 2025-09-28 05:04:39 - browse：63626

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Lawsuit highlights wrinkle for disputes over surprise medical bills

explore

WSS

AstraZeneca stays mum on Medicare drug pricing negotiations

Bernie brings in new pharma CEOs to talk drug prices

Adopting new red light myopia treatments may be short

Why CTE doesn’t keep Americans from enjoying the Super Bowl

RSV injection headlines need to be accurate for good uptake

Setback for rare diseases as Taysha Gene Therapies pulls back

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Johnson & Johnson sued for allegedly overpaying for workers' drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Some top drug companies are starting to take action on climate

New air purifier tech could be key to improving indoor air quality

Will an HIV vaccine ever be a reality?

How one medical school became remarkably diverse

The Biogen Aduhelm mess could happen again

23andMe had bad news about my health. I wish a person had delivered it

Adopting new red light myopia treatments may be short

knowledge

Congress extends some pandemic preparedness programs

Top private equity targets in 2023: cardiology, clinical trials, lasers

6 solutions to address cancer drug shortages and others

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Medicare Advantage plans can’t deny care with AI, CMS warns

focus

explore

Wikipedia

entertainment